Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
We are achieving the target of developed India by making our young children healthy today
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
Subscribe To Our Newsletter & Stay Updated
